JW LifescienceJW생명과학
234080 · KOSPI · ₩234080 · JW생명과학
- Market cap
- ₩165B
- Enterprise value
- ₩186B
- P/E
- 5.1×
- P/B
- 0.7×
- Dividend yield
- 0.0%
- ROE
- 14.2%
- Net margin
- 12.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−33.1% from the high
₩10,330Today: ₩10,350 – ₩10,580₩15,580
Returns
- 1W−2.5%
- 1M−5.1%
- 3M−7.0%
- 6M−19.5%
- YTD−18.9%
- 1Y−21.7%
- Volume today
- 16,300
- 1.0× the 20-day average
- Traded today
- ₩170M
- Listed shares
- 15,834,554
- EPS (12 months)
- ₩2,029
- Earnings yield 19.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
JW Lifescience stock overview
JW Lifescience (JW생명과학, KRX: 234080) is listed on KOSPI, in the Biotech & Pharma sector. JW Life Science manufactures and sells intravenous (IV) fluids and related pharmaceuticals, including basic fluids, special fluids, nutrition fluids, total parenteral nutrition (TPN) products, and dialysis fluids, with its main customers being affiliate JW Pharmaceutical and other B2B buyers. Its shares closed at ₩10,420 on Oct 26, 2026, down 0.95% on the day, giving it a market value of ₩165B.
Key facts
- Market cap
- ₩165B
- Sector
- Biotech & Pharma
- Latest price change
- −0.95%
- As of
- Oct 26, 2026
- Main business
- JW Life Science manufactures and sells intravenous (IV) fluids and related pharmaceuticals, including basic fluids, special fluids, nutrition fluids, total parenteral nutrition (TPN) products, and dialysis fluids, with its main customers being affiliate JW Pharmaceutical and other B2B buyers.
Quick answers about JW Lifescience
- What does JW Lifescience do?
- JW Life Science manufactures and sells intravenous (IV) fluids and related pharmaceuticals, including basic fluids, special fluids, nutrition fluids, total parenteral nutrition (TPN) products, and dialysis fluids, with its main customers being affiliate JW Pharmaceutical and other B2B buyers. The company exports its products, has a licensing and supply agreement with US company Baxter, and operates a manufacturing plant in Dangjin, South Korea.
- What is the market cap of JW Lifescience?
- The market capitalisation of JW Lifescience was ₩165B at the close on Oct 26, 2026.
- Who are the largest shareholders of JW Lifescience?
- According to the latest official filings, the largest reported holders are FILLIMITED (9.72%, as of Jul 10, 2026); National Pension Service (0.72%, as of Dec 31, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.34%, as of Jul 31, 2026).
- When is the next earnings report from JW Lifescience?
- Korean companies rarely announce results dates in advance. Based on when JW Lifescience filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own JW Lifescience?
- Yes. The National Pension Service held 0.72% of JW Lifescience shares as of Dec 31, 2025.
Company profile
JW Life Science manufactures and sells intravenous (IV) fluids and related pharmaceuticals, including basic fluids, special fluids, nutrition fluids, total parenteral nutrition (TPN) products, and dialysis fluids, with its main customers being affiliate JW Pharmaceutical and other B2B buyers. The company exports its products, has a licensing and supply agreement with US company Baxter, and operates a manufacturing plant in Dangjin, South Korea.
Written by AI from the company's latest annual report.
- Korean name
- JW생명과학
- Sector
- Biotech & Pharma
- CEO
- 노정열
- Founded
- May 1994
- Listed
- Oct 2016
- Listed shares
- 15,834,554
- Fiscal year ends
- Month 12
- Website
- www.jw-lifescience.co.kr
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earningsAug 12, 2026
- 5%+ holding reportJul 10, 2026
- Disclosure of Corporate Governance ReportJun 1, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: JW Lifescience / JW생명과학 / 234080 / KRX:234080
Source: KRX statistical information